PGmax™ - Comprehensive Congenital Heart Disease Panel
Use
The PGmax™ - Comprehensive Congenital Heart Disease Panel is designed for individuals who have a clinical or suspected diagnosis of congenital heart disease. This panel is ideal for patients with syndromic features in addition to congenital heart defects and for individuals with a family history of congenital heart defects. The test provides valuable genetic insights that can aid in diagnosis, management, and genetic counseling.
Special Instructions
This test includes both Exome and Genome platform options for a comprehensive analysis. Exome-Wide CNV Analysis is included. Prenatal and STAT testing options are available. Ensure all relevant clinical information is provided to facilitate accurate interpretation of results.
Limitations
Performance characteristics of the test have been validated following CAP and CLIA guidelines, though the test has not been cleared or approved by the FDA. Variants may not be detected if the coverage is insufficient, and certain complex genomic regions may pose challenges for analysis. The test may not detect all causes of congenital heart disease due to limitations in current genomic knowledge.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
14-28 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided